Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Medicine is poised to undergo a digital transformation. High-throughput platforms are
creating terabytes of genomic, transcriptomic, proteomic, and metabolomic data. The …

Abstract Purpose of Review Chronic myeloid leukemia (CML) patients with constitutive
activity of BCR-ABL1 oncoprotein frequently derive significant clinical benefits from tyrosine …

Introduction: The tyrosine kinase inhibitor (TKI) imatinib was rationally designed to target
BCR-ABL1 which is constitutively activated in chronic myeloid leukemia (CML). Following …

Objective This study intended to establish a droplet digital PCR (dd‐PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …

Background Although, molecular genetic analyses became more and more important to
guide therapy decisions in leukemia, banding cytogenetic analysis has retained its vital role …

Multidrug resistance (MDR) usually causes chemotherapy failure of chronic myelogenous
leukemia (CML). Germacrone is a terpenoid compound and has been reported to reverse …

Background Accurate quantification of the BCR:: ABL1 transcripts is essential for
measurable residual disease (MRD) monitoring in chronic myeloid leukemia (CML) after …

Lung cancer is one of the leading causes of cancer death among both men and women,
making up almost 25% of all cancer deaths. Precision medicine shows promise for …

Simple, sensitive and specific detection of the transcription level of BCR-ABL1 mRNA
possesses vital clinical significance in diagnosis and treatment of chronic myeloid leukemia …